Commercial Health Insurances as an access route to the Chinese market
In an article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion.
Inflation Reduction Act: Implications for US Healthcare and Pharmaceutical Industries
On August 16th, 2022, President Biden signed the Inflation Reduction Act into law, which will bring reforms to Medicare spending and coverage, impacting manufacturers’ long-term P&MA strategy and payer decision-making.
The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions
Windrose Consulting Group’s take on The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions.
Global News Roundup: Q2 2022
We are pleased to release the next edition of our Windrose Consulting Group: Global News Roundup for Q2 2022.
Q&A – with Daisy Pharoah, Analyst at Windrose Consulting Group
In this Q&A, we are featuring Daisy Pharoah and her career journey and highlights to date.
“Uncertainty has been weaponised by payers”
Last week during the second session of our P&MA strategy course (a collaboration between Windrose and Cambridge University), our guest Andrew Walker produced this nugget:
“Uncertainty has been weaponised by payers”
Biogen pulls their European application for Aduhelm
On Friday, April 22nd, 2022, Biogen announced that it had withdrawn the marketing application in the EU for aducanumab (Aduhelm), its monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of Alzheimer’s patients.
Global News Roundup: Q1 2022
We are pleased to release the second edition of our Windrose Consulting Group: Global News Roundup for Q1 2022.
The Rewards and Challenges of Biomarkers in Pricing & Market Access
The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.
German Drug Pricing Reforms: What do they mean for P&MA?
This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.
Medicare’s Aduhelm NCD Has Implication Outside of Alzheimer’s Disease
As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).
World AIDS Day, 1 December 2021
December 1st is World AIDS Day and is an opportunity to reflect on pharmacological innovations that has turned a once fatal disease into a treatable condition. Infection rates have slowed in recent years due to increase in testing availability, as well as development of antiretroviral therapy and, more recently, pre-exposure prophylaxis (PrEP)
Global News Roundup: Q1-Q3 2021
We are pleased to launch the first edition of our Windrose Consulting Group: Global News Roundup for Q1-Q3 2021.
Aduhelm vs. Exondys-51: Understanding the disparity in launch success of two similarly uncertain evidence packages
In June, Windrose’s Elizaveta Tchebaniouk provided an analysis of Aduhelm’s approval in Alzheimer’s Disease (AD) and the dynamic environment surrounding Biogen’s launch in the US. High unmet need, uncertain evidence, modest clinical benefit, and affordability concerns continue to make for a highly complex commercial launch.
Aduhelm Approval Brings Potential for an Evolving Alzheimer’s Disease Treatment Market and Challenges for Healthcare Costs
On June 7th, the FDA granted accelerated approval for Biogen’s amyloid beta-directed anti-body Aduhelm (aducanumab), the first potentially disease-modifying treatment and first approval for Alzheimer’s disease (AD) in nearly two decades.